Ozempic vs Wegovy vs Mounjaro: Side Effects Compared Week by Week
Semaglutide and tirzepatide cause similar but not identical side effects. Here's how Ozempic, Wegovy, and Mounjaro compare across nausea, energy, and appetite over time.
Ozempic, Wegovy, Mounjaro, and Zepbound are often discussed as interchangeable, but they're not identical — and the side effect profile differs enough between them that it's worth understanding before comparing notes with someone on a different medication (or wondering why your experience doesn't match what you've read).
The core difference: GLP-1 alone vs. dual-agonist
Ozempic and Wegovy (both semaglutide) work as GLP-1 receptor agonists — they act on one hormonal pathway involved in appetite regulation and gastric emptying.
Mounjaro and Zepbound (both tirzepatide) are dual GIP/GLP-1 receptor agonists — they act on two pathways instead of one. This is part of why tirzepatide-based medications tend to show somewhat greater average weight loss in clinical trials, but it also means the side effect experience isn't always a direct match to semaglutide.
Ozempic and Wegovy are the same active compound at different dose ranges (Ozempic is approved for diabetes, Wegovy for weight management, with different titration schedules) — so side effect patterns between them are usually more similar to each other than either is to Mounjaro or Zepbound.
Nausea and GI side effects
Both drug classes cause nausea, primarily through slowed gastric emptying. In practice, many people report the nausea pattern feels broadly similar between semaglutide and tirzepatide, though individual tolerance varies widely — some people find one medication noticeably more tolerable than the other, without a consistent pattern across the population.
Constipation tends to be a common thread across both drug classes, often more persistent than nausea and sometimes underreported because it doesn't resolve as cleanly over the first few weeks the way nausea often does.
Appetite suppression intensity
Because tirzepatide acts on two receptor pathways, some people report a more pronounced appetite suppression on Mounjaro or Zepbound compared to semaglutide at equivalent points in titration. This isn't universal, but it's a commonly reported difference — and it means protein and hydration targets may need even more deliberate attention on a dual-agonist medication, since appetite suppression working "too well" can make it harder to eat enough of anything.
Energy levels
Early-phase fatigue is commonly reported across all four medications, generally attributed to reduced calorie intake combined with the body adjusting to the new hormonal signaling. This tends to improve over the first several weeks as eating patterns stabilize, regardless of which specific medication is being used.
Titration schedules differ
Wegovy and Zepbound (the weight-management-labeled versions) follow more gradual, structured dose-escalation schedules than the diabetes-labeled Ozempic and Mounjaro, which can sometimes be titrated faster depending on the prescriber's approach. This matters because a faster titration schedule often means a more compressed, more intense side-effect window — so two people on "the same" medication class can have meaningfully different experiences based on how quickly their dose increased.
What this means practically
If you're comparing notes with someone on a different GLP-1 medication and your experiences don't match, that's expected — different receptor targets, different titration speeds, and individual variation all play a role. The more useful comparison isn't "how does my experience compare to someone else's," but "how does my week 6 compare to my own week 2" — which is where tracking your own pattern over time tends to be more informative than comparing across medications or people.
This article is educational and not a substitute for medical advice. Medication choice and dosing should always be determined with your prescriber based on your individual health profile.
Not medical advice. Always consult your healthcare provider.